HilleVaxHLVX
HLVX
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
113% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 15
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
21% more capital invested
Capital invested by funds: $73.5M [Q3] → $88.7M (+$15.2M) [Q4]
2.13% more ownership
Funds ownership: 83.87% [Q3] → 86.0% (+2.13%) [Q4]
4% less funds holding
Funds holding: 79 [Q3] → 76 (-3) [Q4]
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
44%
upside
Avg. target
$2
44%
upside
High target
$2
44%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Matthew Caufield 33% 1-year accuracy 21 / 63 met price target | 44%upside $2 | Neutral Reiterated | 31 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
4 days ago
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the year ended December 31, 2024. Full Year 2024 Financial Results As of December 31, 2024 and December 31, 2023, the company had cash, cash equivalents and marketable securities totaling $171.4 million and $303.5 million, respectively.

Positive
Zacks Investment Research
5 months ago
What Makes HilleVax (HLVX) a New Buy Stock
HilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Neutral
Accesswire
7 months ago
HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Neutral
Accesswire
7 months ago
Levi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Neutral
Accesswire
7 months ago
Investors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVX
NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Neutral
Accesswire
7 months ago
HilleVax, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HLVX
NEW YORK, NY / ACCESSWIRE / August 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Neutral
Accesswire
7 months ago
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Neutral
Accesswire
7 months ago
ATTENTION HLVX SHAREHOLDERS: Investors who Lost Money on HilleVax, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Neutral
Accesswire
7 months ago
HLVX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your HilleVax, Inc. investment
NEW YORK, NY / ACCESSWIRE / August 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.

Neutral
Accesswire
7 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or the "Company") (NASDAQ:HLVX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Charts implemented using Lightweight Charts™